Judith K. Wolf, MD
Associate Professor, Department of Gynecologic Oncology
University of Texas M.D. Anderson Cancer Center
Ovarian cancer is the most common cause of death from gynecologic malignancies and remains the fifth leading cause of cancer death in women in the United States. Because early disease is difficult to detect and there are currently no effective screening protocols, women are often not diagnosed with ovarian cancer until the disease has progressed to an advanced stage. A comprehensive approach to the management of ovarian cancer is critical to ensuring the most effective patient outcomes.
This program is designed to enhance the knowledge and understanding of recent advancements in the treatment of ovarian cancer. Recent clinical trials and effective methods to improve the quality of life in patients undergoing cancer treatment will be reviewed. Any clinician who cares for women with ovarian cancer will benefit from this presentation, which was developed by experts in ovarian cancer treatment.
. Target Audience
Oncologists, oncology nurses, and other healthcare providers who care for women with ovarian cancer.
Upon completion of this educational activity, the participant should be able to:
Discuss the staging of ovarian cancer and the role of surgery
Review efficacy, side-effect profiles, and toxicity of first and second-line chemotherapy agents
Summarize the role of hematopoietic growth factors in preventing and treating chemotherapy-related anemia and decreasing transfusion requirements
Identify ways to improve the quality of life in patients undergoing chemotherapy
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Judith K. Wolf, MD discloses that she is a speakers’ bureau member for Ortho Biotech.
This educational activity may contain discussion of published and/or investigational uses of oncology agents. Some uses may not have been approved by the FDA. The faculty have agreed to disclose discussion of off-label use during her presentation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media.
AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
AKH Inc. designates this educational activity for 1.0 contact hour (0.1 CEU). Commercial Support Statements
Funded by an educational grant from Ortho Biotech.
Please turn off all pop-up blockers.
Click on the “start program” icon. This will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or update/correct existing registration information. When ready, click on the “continue to program” icon at the bottom of the screen. This will take you to a brief pre-program survey.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking “start the virtual meeting” will allow you to begin the program presentation. The program will require approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation. This will bring you to a brief post-program survey.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CE statement of credit. Two attempts are allowed.
©2007, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this activity are those of the presenter and do not necessarily reflect the opinions or recommendations of her affiliated institutions, the publisher, AKH Inc., or Ortho Biotech. Any medications or other diagnostic or treatment procedures discussed by the program faculty should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.